B

BioAtla, Inc.

62 employees

BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
antibody evolution and engineering
Health Care
conditionally active biologics
Medical
protein evolution and engineering
development of novel cancer immunotherapies

Date founded

2007

Funding rounds raised

Total raised

$75M

from 14 investors over 14 rounds

B

BioAtla, Inc. raised $65M on November 4, 2022

Investors: Adage Capital Management, Acuta Capital, Vivo Capital and Soleus Capital Management, L.P.

B

BioAtla, Inc. raised $75M on September 29, 2021

Investors: Ikarian Capital LLC, Great Point Partners, Monashee Investment Management LLC, Hudson Bay Capital Management LP, Soleus Capital Management, L.P. and Pappas Capital

B

BioAtla, Inc. raised $73M on July 15, 2020

Investors: Pappas Capital, Farallon Capital Management and Soleus Capital Management, L.P.

B

BioAtla, Inc. raised $39M on July 21, 2015

Investors: Temerity Capital Partners

FAQ